Endometriosis Therapy with Gestrinone by Oral, Vaginal or Parenteral Administration
article
OA: closed
CC0
⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper investigated the efficacy and tolerability of gestrinone therapy for endometriosis administered orally, vaginally, or parenterally.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (3)
- A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis 1990
- Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1 2007
- Treatment of Refractory Endometriosis-Related Pain with Vaginal Gestrinone in Pentravan Associated with Pinus Pinaster Extract and Resveratrol: A Preliminary Study 2014
Cited by (3)
- Treatment of Refractory Endometriosis-Related Pain with Vaginal Gestrinone in Pentravan Associated with Pinus Pinaster Extract and Resveratrol: A Preliminary Study 2014
- Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1 2007
- A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis 1990
Source provenance
- europepmc
- last seen: 2026-08-17T06:11:01.428247+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:09:30.565292+00:00
- unpaywall
- last seen: 2026-08-17T06:25:09.426038+00:00
License: CC0
· commercial use OK